Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A1 | O15245 | 4/20 | 0.75 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | DNM1 | Q05193 | 6/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrabuthylammonium SCHEMBL9221599 | 0.87 | SLC22A1 (0.86) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL71525 | 0.87 | SLC22A1 (1.00) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL22384 | 0.87 | SLC22A1 (1.00) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL2007037 | 0.87 | SLC22A1 (1.00) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL27772483 | 0.84 | SLC22A1 (0.80) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL6690901 | 0.84 | SLC22A1 (0.80) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL3343598 | 0.84 | SLC22A1 (0.80) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL25195464 | 0.83 | SLC22A1 (0.92) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL2007036 | 0.83 | SLC22A1 (0.92) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL2580744 | 0.83 | SLC22A1 (0.92) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016133946-A1 | MICROCAPSULES HAVING ENCAPSULTED CATALYSTS | DOW CORNING CORPORATION (US) | 2016-08-25 | — | — | WO | claimed |
| EP-3119394-B1 | COMPOSITIONS AND METHODS COMPRISING 2-(ACYLAMINO)IMIDAZOLES | CURZA GLOBAL LLC (US) | 2021-05-12 | — | — | EP | disclosed |
| US-10493061-B2 | Compositions and methods comprising 2-(acylamino)imidazoles | CURZA GLOBAL, LLC (US) | 2019-12-03 | — | — | US | disclosed |
| US-20170267836-A1 | Process For Preparing Ethylenedialkylphosphinic Acids, Esters And Salts And Use Thereof | CLARIANT PLASTICS & COATINGS LTD (CH) | 2017-09-21 | — | — | US | disclosed |
| US-20170100375-A1 | COMPOSITIONS AND METHODS COMPRISING 2-(ACYLAMINO)IMIDAZOLES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-04-13 | — | — | US | disclosed |
| WO-2016133946-A1 | MICROCAPSULES HAVING ENCAPSULTED CATALYSTS | DOW CORNING CORPORATION (US) | 2016-08-25 | — | — | WO | disclosed |
| US-9279085-B2 | Method for the production of monofunctionalized dialkylphosphinic acids, esters and salts, and use thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2016-03-08 | — | — | US | disclosed |
| US-9181487-B2 | Process for preparing ethylenedialkylphosphinic acids, esters and salts by means of acetylene and use thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2015-11-10 | — | — | US | disclosed |
| US-9139714-B2 | Method for producing dialkylphosphinic acids and esters and salts thereof by means of allyl alcohols-acroleins and use thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2015-09-22 | — | — | US | disclosed |
| US-9085734-B2 | Process for preparing mono-carboxy-functionalized dialkylphosphinic acids, esters and salts by means of alkylene oxides and use thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2015-07-21 | — | — | US | disclosed |
| US-7097781-B2 | Method for manufacturing porous structure and method for forming pattern | KABUSHIKI KAISHA TOSHIBA (JP) | 2006-08-29 | — | — | US | disclosed |
| US-7090784-B2 | Forming pattern using graft polymer containing metal particles; overcoating substrates; removal polymer | KABUSHIKI KAISHA TOSHIBA (JP) | 2006-08-15 | — | — | US | disclosed |
| US-20040227446-A1 | Display device and method of manufacturing transparent substrate for display device | KABUSHIKI KAISHA TOSHIBA (JP) | 2004-11-18 | — | — | US | disclosed |
| US-20040050816-A1 | Forming pattern using graft polymer containing metal particles; overcoating substrates; removal polymer | KABUSHIKI KAISHA TOSHIBA (JP) | 2004-03-18 | — | — | US | disclosed |
| US-20030222048-A1 | Method for manufacturing porous structure and method for forming pattern | KABUSHIKI KAISHA TOSHIBA (JP) | 2003-12-04 | — | — | US | disclosed |
| US-6565763-B1 | Method for manufacturing porous structure and method for forming pattern | KABUSHIKI KAISHA TOSHIBA (JP) | 2003-05-20 | — | — | US | disclosed |
| EP-0632063-B1 | Bimetallic metallocene alumoxane catalyst system and its use in the preparation of ethylene copolymers | BAYER INC (CA) | 1998-08-12 | — | — | EP | disclosed |
| US-5442020-A | Reacting ethylene and alpha-olefin under pressure in liquid phase in presence of catalyst system containing zirconium metallocene with silanylene bridge and alumoxane | POLYSAR RUBBER CORPORATION (CA) | 1995-08-15 | — | — | US | disclosed |
| EP-0632063-A1 | Bimetallic metallocene alumoxane catalyst system and its use in the preparation of ethylene copolymers | BAYER RUBBER INC. (CA) | 1995-01-04 | — | — | EP | disclosed |
| US-5372980-A | Bimetallic metallocene alumoxane catalyst system and its use in the preparation of ethylene-alpha olefin and ethylene-alpha olefin-non-conjugated diolefin elastomers | POLYSAR (CA) | 1994-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10493061-B2 | Compositions and methods comprising 2-(acylamino)imidazoles | AADAC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HDAC6 | SLC22A1 2085/4885SLC22A2 1770/4885ALDH1A1 1008/4885 |
| US-20170100375-A1 | COMPOSITIONS AND METHODS COMPRISING 2-(ACYLAMINO)IMIDAZOLES | AADAC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HDAC6 | SLC22A1 2085/4885SLC22A2 1770/4885ALDH1A1 1008/4885 |
| US-20170267836-A1 | Process For Preparing Ethylenedialkylphosphinic Acids, Esters And Salts And Use Thereof | ENPP1, ENPP3, FADS2 | SLC22A1 2847/4885SLC22A2 3137/4885ALDH1A1 983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.